Search ↗

Classes

Other

Compounds that do not fall cleanly into the other classes.

1 compounds in this class. 0 approved by the FDA for at least one indication. 0 have no published human trial data.

All 1 other compared

CompoundEvidenceReported rangeHalf-lifeStatus
VIP
A 28-residue neuropeptide with broad vasodilatory and immunomodulatory activity, trialled as aviptadil in acute respiratory failure.
 Clinical trials 50-150 mcg ~1-2 minutes Research only

Head-to-head comparisons

KPV vs VIPThymosin Alpha-1 vs VIP

Other: common questions

What are other?

Compounds that do not fall cleanly into the other classes. This class has 1 compounds in our directory.

Which other are FDA approved?

None of the 1 compounds in this class is FDA approved for any indication.

Which other have the strongest evidence?

By evidence level and number of human studies: VIP (clinical trials, ~12 human studies).

Can compounding pharmacies make these?

VIP is not FDA approved and not on the 503A bulks list, so there is no routine legal path to compound it. Material sold online is labelled for research use only. Status checked against FDA lists in October 2026.

References

Regulatory and primary sources

  1. FDA: Bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) ↗ · content current as of April 22, 2026; checked October 18, 2026
  2. FDA: Bulk drug substances used in compounding under section 503A ↗ · how the 503A categories work
  3. FDA: Unapproved drugs ↗ · status of products sold "for research use only"
  4. WADA Prohibited List ↗ · peptide hormones and growth factors, class S2
  5. PubMed (National Library of Medicine) ↗ · source of every literature reference on this site

Published literature

  1. Fahrenkrug J. VIP and PACAP.Results Probl Cell Differ 2010.PubMed 19859678 · doi:10.1007/400_2009_24
  2. García-García F, Acosta-Peña E, Venebra-Muñoz A, et al.. Sleep-inducing factors.CNS Neurol Disord Drug Targets 2009.PubMed 19689305 · doi:10.2174/187152709788921672
  3. Tajti J, Szok D, Majláth Z, et al.. Migraine and neuropeptides.Neuropeptides 2015.PubMed 26094101 · doi:10.1016/j.npep.2015.03.006
  4. Tervo T, Tervo K, Eränkö L. Ocular neuropeptides.Med Biol 1982.PubMed 6178909
  5. McConalogue K, Furness JB. Gastrointestinal neurotransmitters.Baillieres Clin Endocrinol Metab 1994.PubMed 7907863 · doi:10.1016/s0950-351x(05)80226-5
  6. Krejs GJ. VIPoma syndrome.Am J Med 1987.PubMed 3035922 · doi:10.1016/0002-9343(87)90425-6
  7. Youssef JG, Lavin P, Schoenfeld DA, et al.. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Crit Care Med 2022.PubMed 36044317 · doi:10.1097/CCM.0000000000005660
  8. Barnes PJ. Neuropeptides and asthma.Am Rev Respir Dis 1991.PubMed 1706152 · doi:10.1164/ajrccm/143.3_Pt_2.S28

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.